Pancreatic Cancer Research

ResearcherAsahikawa Medical UniversityActive in the last 2 years

Yohei Kitano

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5091734517. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 8

  1. Extracellular vesicle-encapsulated microRNA-425 promotes tumor development and serves as a biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02382-9↗
  2. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  3. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  4. Liquid Biopsy for Pancreatic Cancer by Serum Extracellular Vesicle-Encapsulated Long Noncoding RNA HEVEPA. Co-author DOI 10.1097/mpa.0000000000002315↗
  5. HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-022-14094-0↗
  6. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  7. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer. Co-author DOI 10.1111/cas.14232↗
  8. The Interaction Between Long Non-coding RNA HULC and MicroRNA-622 via Transfer by Extracellular Vesicles Regulates Cell Invasion and Migration in Human Pancrea… Last author DOI 10.3389/fonc.2020.01013↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenji Takahashi · 4 shared papers, 2020–2026 · strength 0.62
  2. Kazuya Koyama · 3 shared papers, 2020–2026 · strength 0.51
  3. Kunihiro Tsuji · 3 shared papers, 2022–2025 · strength 0.43
  4. Kumiko Umemoto · 3 shared papers, 2022–2025 · strength 0.43
  5. Satoshi Kobayashi · 3 shared papers, 2022–2025 · strength 0.43
  6. Rei Suzuki · 3 shared papers, 2022–2025 · strength 0.43
  7. Naohiro Okano · 3 shared papers, 2022–2025 · strength 0.43
  8. Hiroshi Imaoka · 3 shared papers, 2022–2025 · strength 0.43
  9. Junji Furuse · 3 shared papers, 2022–2025 · strength 0.43
  10. Makoto Ueno · 3 shared papers, 2022–2025 · strength 0.43
  11. Mikihiro Fujiya · 2 shared papers, 2024–2026 · strength 0.39
  12. Hidemasa Kawabata · 2 shared papers, 2024–2026 · strength 0.39
  13. Yusuke Mizukami · 2 shared papers, 2024–2026 · strength 0.39
  14. Toshikatsu Okumura · 2 shared papers, 2024–2026 · strength 0.39
  15. Akinori Asagi · 2 shared papers, 2025 · strength 0.32
  16. Nana Kimura · 2 shared papers, 2025 · strength 0.32
  17. Takeshi Terashima · 2 shared papers, 2025 · strength 0.32
  18. Masayuki Ueno · 2 shared papers, 2025 · strength 0.32
  19. Masafumi Ikeda · 2 shared papers, 2025 · strength 0.32
  20. Toshifumi Doi · 2 shared papers, 2025 · strength 0.32
  21. Reiko Ashida · 2 shared papers, 2025 · strength 0.32
  22. Kohei Nakachi · 2 shared papers, 2025 · strength 0.32
  23. Hiroaki Nagano · 2 shared papers, 2025 · strength 0.32
  24. Yasuyuki Kawamoto · 2 shared papers, 2025 · strength 0.32
  25. Akihiro Ohba · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.